Skip to main content

Emerald BioStructures, UCB Expand Drug Discovery Collaboration

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Emerald BioStructures and UCB today said that they have a achieved a second milestone in their ongoing collaboration and have expanded the alliance.

Bainbridge Island, Wash.-based Emerald said that it and UCB researchers have solved high-resolution X-ray crystallographic structures of multiple targets and have identified a unique lead series of small molecules. The firm said that it achieved that milestone within two years, since the firms initiated their collaboration in January 2009.

Emerald also said that the firms have decided to expand the agreement, though it provided few details. The expansion will result in undisclosed research fees, a milestone payment, and royalties. Emerald said that the financial terms would support multiple full-time researcher equivalents at the firm.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.